| Accent Group |
AX1 |
Citi raises Accent Group (AX1) price target from $1.550 to $1.600. Retains neutral rating. |
| Accent Group |
AX1 |
Morgan Stanley raises Accent Group (AX1) price target from $1.900 to $2.00. Retains overweight rating. |
| Adbri |
ABC |
UBS upgrades Adbri (ABC) rating from sell to neutral. Raises price target from $2.03 to $2.40. Cites better than expected performance in H1 results. |
| Afterpay |
APT |
Goldman Sachs raises Afterpay (APT) price target from $71.95 to $93.45. Retains neutral rating. Broker is impressed with growth, and further notes that it is likely to continue as addressable market is also growing rapidly. |
| Afterpay |
APT |
UBS raises Afterpay (APT) price target from $27.00 to $28.25. Retains sell rating. |
| Afterpay |
APT |
Macquarie retains neutral rating on Afterpay (APT). Retains $90.00 price target. |
| Afterpay |
APT |
Morgan Stanley retains overweight rating on Afterpay (APT). Retains $106.00 price target. |
| Ainsworth Game Technology |
AGI |
Macquarie lowers Ainsworth Game Technology (AGI) price target from $0.500 to $0.450. Retains neutral rating. |
| Appen |
APX |
Credit Suisse downgrades Appen (APX) rating from neutral to underperform. Lowers price target from $30.00 to $29.00. Blames lack of positive guidance in H1 results, notes weaker than expected. |
| Appen |
APX |
Macquarie raises Appen (APX) price target from $38.00 to $43.00. Retains outperform rating. |
| Appen |
APX |
UBS raises Appen (APX) price target from $41.00 to $44.00. Retains buy rating. |
| Ardent Leisure Group |
ALG |
Citi lowers Ardent Leisure Group (ALG) price target from $1.230 to $0.690. Retains buy rating. Blames continued headwinds for business, execution misses. |
| Atlas Arteria |
ALX |
Goldman Sachs raises Atlas Arteria (ALX) price target from $7.20 to $8.17. Retains buy rating. |
| Atlas Arteria |
ALX |
Credit Suisse upgrades Atlas Arteria (ALX) rating from neutral to outperform. Raises price target from $6.90 to $7.90. Broker is impressed with recovery in France traffic volumes, optimistic on continued recovery elsewhere. |
| Atlas Arteria |
ALX |
Macquarie raises Atlas Arteria (ALX) price target from $6.71 to $6.81. Retains neutral rating. Notes recovery in traffic volumes. |
| Atlas Arteria |
ALX |
Morgan Stanley raises Atlas Arteria (ALX) price target from $6.88 to $6.91. Retains equalweight rating. Sees positive signs in traffic volume recovery. |
| Atlas Arteria |
ALX |
UBS raises Atlas Arteria (ALX) price target from $6.35 to $6.50. Retains neutral rating. Cites better than expected H1 results. |
| Capitol Health |
CAJ |
Credit Suisse raises Capitol Health (CAJ) price target from $0.290 to $0.300. Retains outperform rating. |
| City Chic Collective |
CCX |
Macquarie raises City Chic Collective (CCX) price target from $4.21 to $4.30. Retains outperform rating. |
| Flight Centre Travel Group |
FLT |
Citi raises Flight Centre Travel Group (FLT) price target from $13.50 to $14.10. Retains neutral rating. |
| Flight Centre Travel Group |
FLT |
Credit Suisse raises Flight Centre Travel Group (FLT) price target from $13.46 to $14.01. Retains outperform rating. |
| Flight Centre Travel Group |
FLT |
UBS lowers Flight Centre Travel Group (FLT) price target from $15.10 to $14.50. Retains buy rating. |
| Galaxy Resources |
GXY |
Citi raises Galaxy Resources (GXY) price target from $1.100 to $1.250. Retains neutral rating. |
| GTN |
GTN |
Macquarie lowers GTN (GTN) price target from $0.530 to $0.470. Retains neutral rating. |
| Harvey Norman |
HVN |
Citi raises Harvey Norman (HVN) price target from $4.60 to $4.80. Retains buy rating. |
| IGO |
IGO |
Credit Suisse upgrades IGO (IGO) rating from underperform to neutral. Raises price target from $4.05 to $4.35. |
| IGO |
IGO |
Morgan Stanley raises IGO (IGO) price target from $4.75 to $4.80. Retains equalweight rating. |
| Japara Healthcare |
JHC |
UBS lowers Japara Healthcare (JHC) price target from $0.600 to $0.500. Retains neutral rating. |
| Life360 |
360 |
Credit Suisse raises Life360 (360) price target from $4.40 to $4.80. Retains outperform rating. |
| Link Administration |
LNK |
Credit Suisse lowers Link Administration (LNK) price target from $5.90 to $5.10. Retains outperform rating. |
| Link Administration |
LNK |
Macquarie raises Link Administration (LNK) price target from $4.60 to $5.10. Retains outperform rating. |
| Link Administration |
LNK |
UBS raises Link Administration (LNK) price target from $4.65 to $4.80. Retains buy rating. |
| Metcash |
MTS |
Goldman Sachs raises Metcash (MTS) price target from $3.27 to $3.45. Retains buy rating. Broker is impressed with accelerating sales growth across all three of co's divisions. |
| Nine Entertainment Co. |
NEC |
Jefferies raises Nine Entertainment Co. (NEC) price target from $1.790 to $1.990. Retains buy rating. Is pleased with the performance of co's digital assets. FY20 results were better than expected. |
| Nine Entertainment Co. |
NEC |
Credit Suisse raises Nine Entertainment Co. (NEC) price target from $2.10 to $2.35. Retains outperform rating. Broker is impressed with Stan performance. |
| Nine Entertainment Co. |
NEC |
Macquarie raises Nine Entertainment Co. (NEC) price target from $1.650 to $1.900. Retains outperform rating. Expects an uptick in earnings growth led by online. |
| Nine Entertainment Co. |
NEC |
Morgan Stanley raises Nine Entertainment Co. (NEC) price target from $1.950 to $2.10. Retains overweight rating. Notes is becoming more confident in co's ability to return to earning's growth. |
| Nine Entertainment Co. |
NEC |
UBS raises Nine Entertainment Co. (NEC) price target from $1.750 to $1.900. Retains buy rating. Expects operating conditions to improve. |
| Platinum Asset Management |
PTM |
Credit Suisse raises Platinum Asset Management (PTM) price target from $3.15 to $3.30. Retains underperform rating. |
| Platinum Asset Management |
PTM |
Macquarie lowers Platinum Asset Management (PTM) price target from $3.50 to $3.40. Retains underperform rating. |
| Prospa Group |
PGL |
Macquarie lowers Prospa Group (PGL) price target from $0.940 to $0.870. Retains neutral rating. |
| Prospa Group |
PGL |
UBS lowers Prospa Group (PGL) price target from $1.400 to $0.900. Retains neutral rating. |
| Ramsay Health Care |
RHC |
Citi lowers Ramsay Health Care (RHC) price target from $72.00 to $70.00. Retains neutral rating. |
| Ramsay Health Care |
RHC |
Credit Suisse raises Ramsay Health Care (RHC) price target from $68.80 to $70.00. Retains outperform rating. |
| Ramsay Health Care |
RHC |
Macquarie raises Ramsay Health Care (RHC) price target from $72.50 to $73.15. Retains outperform rating. |
| Ramsay Health Care |
RHC |
Morgan Stanley raises Ramsay Health Care (RHC) price target from $56.00 to $61.00. Retains underweight rating. |
| Reece |
REH |
Citi raises Reece (REH) price target from $8.55 to $9.60. Retains sell rating. |
| Regis Healthcare |
REG |
Macquarie raises Regis Healthcare (REG) price target from $1.090 to $1.100. Retains underperform rating. |
| Regis Healthcare |
REG |
UBS lowers Regis Healthcare (REG) price target from $1.500 to $1.360. Retains neutral rating. |
| Sandfire Resources |
SFR |
Citi raises Sandfire Resources (SFR) price target from $5.40 to $5.50. Retains neutral rating. |
| Sandfire Resources |
SFR |
Credit Suisse lowers Sandfire Resources (SFR) price target from $5.50 to $5.40. Retains outperform rating. |
| Sandfire Resources |
SFR |
Macquarie lowers Sandfire Resources (SFR) price target from $5.20 to $5.10. Retains neutral rating. |
| Sandfire Resources |
SFR |
UBS retains buy rating on Sandfire Resources (SFR). Retains $5.80 price target. |
| Seven Group |
SVW |
Goldman Sachs raises Seven Group (SVW) price target from $20.50 to $20.90. Retains buy rating. Notes FY20 results beat expectations. Sees healthy activity levels to support earnings growth. |
| Seven Group |
SVW |
UBS raises Seven Group (SVW) price target from $19.00 to $21.00. Retains buy rating. |
| Sonic Healthcare |
SHL |
Morgan Stanley lowers Sonic Healthcare (SHL) price target from $36.00 to $35.00. Retains overweight rating. Expects some impact on earnings growth as a result of competitor Abbott Labs gaining approval for new covid-19 test. |
| Woolworths Group |
WOW |
Citi lowers Woolworths Group (WOW) price target from $41.50 to $41.20. Retains neutral rating. |
| Woolworths Group |
WOW |
Jefferies raises Woolworths Group (WOW) price target from $44.50 to $46.50. Retains buy rating. Broker believes sales growth intact in the near term, sees gains coming from online offering. |
| Woolworths Group |
WOW |
Credit Suisse raises Woolworths Group (WOW) price target from $37.18 to $40.31. Retains neutral rating. Notes comfortable holding on basis of defensive qualities. |
| Woolworths Group |
WOW |
Morgan Stanley raises Woolworths Group (WOW) price target from $40.50 to $42.00. Retains equalweight rating. Is pleased with strong start to new quarter. |
| Woolworths Group |
WOW |
UBS raises Woolworths Group (WOW) price target from $39.10 to $43.50. Retains buy rating. Broker is impressed with solid cash flow in FY20 results. Sees continued strength ahead. |
| Worley |
WOR |
Goldman Sachs raises Worley (WOR) price target from $12.10 to $12.40. Retains buy rating. Broker is impressed with chemicals division, but notes weakness in energy. Sees continued challenges to hydrocarbon market, but potential upside is compelling. |
| ZIP Co |
Z1P |
Macquarie retains underperform rating on ZIP Co (Z1P). Retains $5.45 price target. Broker is not impressed with FY20 results. Is not sector favourite. |